Clinical Trials
4 trialsNCT06788912 2026-05-26
MK-3475-01E
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT05096663 2026-05-18
Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
SWOG Cancer Research Network
Phase 2/3 Active not recruiting
NCT06616584 2026-05-05
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
SWOG Cancer Research Network
Phase 2/3 Recruiting
NCT05986318 2026-03-09
RESPIRE-ILD
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase 2 Recruiting